Reported 12 months ago
A Delaware judge denied a request by drugmakers, including GSK and Pfizer, to appeal a ruling that over 70,000 Zantac lawsuits alleging the heartburn drug causes cancer can proceed. The judge's decision means the drugmakers will have to seek the state Supreme Court's permission directly to appeal. This paves the way for the cases to potentially go to trial, with the plaintiffs' argument relying on expert testimony linking Zantac to cancer due to the potential NDMA risk from ranitidine. Industry groups supported the drugmakers' appeal, expressing concerns about the standards of evidence in Delaware.
Source: YAHOO